Analytical Data
-
Gene name
HDAC6
- Application
-
Alternative Names
HDAC6；KIAA0901；Histone deacetylase 6
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UBN7
-
Expression Region
1-1215aa
-
AA Sequence
MSPILGYWKIKGLVQPTRLLLEYLEEKYEEHLYERDEGDKWRNKKFELG LEFPNLPYYIDGDVKLTQSMAIIRYIADKHNMLGGCPKERAEISMLEGAV LDIRYGVSRIAYSKDFETLKVDFLSKLPEMLKMFEDRLCHKTYLNGDHVT HPDFMLYDALDVVLYMDPMCLDAFPKLVCFKKRIEAIPQIDKYLKSSKYI AWPLQGWQATFGGGDH PPKSDPMGHHHHHHGRRRASVAAGILVPRGSP GLDGIYARGIQMTSTGQDSTTTRQRRSRQNPQSPPQDSSVTSKRNIKKGA VPRSIPNLAEVKKKGKMKKLGQAMEEDLIVGLQGMDLNLEAEALAGTGLV LDEQLNEFHCLWDDSFPEGPERLHAIKEQLIQEGLLDRCVSFQARFAEKE ELMLVHSLEYIDLMETTQYMNEGELRVLADTYDSVYLHPNSYSCACLASG SVLRLVDAVLGAEIRNGMAIIRPPGHHAQHSLMDGYCMFNHVAVAARYAQ QKHRIRRVLIVDWDVHHGQGTQFTFDQDPSVLYFSIHRYEQGRFWPHLKA SNWSTTGFGQGQGYTINVPWNQVGMRDADYIAAFLHVLLPVALEFQPQLV LVAAGFDALQGDPKGEMAATPAGFAQLTHLLMGLAGGKLILSLEGGYNLR ALAEGVSASLHTLLGDPCPMLESPGAPCRSAQASVSCALEALEPFWEVLV RSTETVERDNMEEDNVEESEEEGPWEPPVLPILTWPVLQSRTGLVYDQNM MNHCNLWDSHHPEVPQRILRIMCRLEELGLAGRCLTLTPRPATEAELLTC HSAEYVGHLRATEKMKTRELHRESSNFDSIYICPSTFACAQLATGAACRL VEAVLSGEVLNGAAVVRPPGHHAEQDAACGFCFFNSVAVAARHAQTISGH ALRILIVDWDVHHGNGTQHMFEDDPSVLYVSLHRYDHGTFFPMGDEGASS QIGRAAGTGFTVNVAWNGPRMGDADYLAAWHRLVLPIAYEFNPELVLVSA GFDAARGDPLGGCQVSPEGYAHLTHLLMGLASGRIILILEGGYNLTSISE SMAACTRSLLGDPPPLLTLPRPPLSGALASITETIQVHRRYWRSLRVMKV EDREGPSSSKLVTKKAPQPAKPRLAERMTTREKKVLEAGMGKVTSASFGE ESTPGQTNSETAVVALTQDQPSEAATGGATLAQTISEAAIGGAMLGQTTS EEAVGGATPDQTTSEETVGGAILDQTTSEDAVGGATLGQTTSEEAVGGAT LAQTTSEAAMEGATLDQTTSEEAPGGTELIQTPLASSTDHQTPPTSPVQG TTPQISPSTLIGSLRTLELGSESQGASESQAPGEENLLGEAAGGQDMADS MLMQGSRGLTDQAIFYAVTPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTI QENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAY VHHQALLDVKNIAHQNKFGEDMPHPH
-
Molecular Weight
161 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
HDAC6 (Histone Deacetylase 6) is a member of the histone deacetylase family, which plays a vital role in various cellular processes, including gene expression regulation, protein degradation, and cellular stress responses. Unlike other HDACs, HDAC6 primarily resides in the cytoplasm and is known for its deacetylase activity on non-histone substrates, particularly affecting the dynamics of microtubules and the regulation of heat shock protein 90 (Hsp90). Its involvement in diverse biological processes has drawn significant attention, as aberrations in HDAC6 activity have been linked to various diseases, including cancer, neurodegenerative disorders, and inflammatory conditions. The ability of HDAC6 to regulate key cellular pathways makes it a promising therapeutic target, leading researchers to explore HDAC6 as a potential biomarker and drug target in personalized medicine. Consequently, the study of recombinant HDAC6 proteins has gained importance, facilitating the elucidation of the enzyme's structure, function, and interactions with pharmacological agents. Such research not only enhances our understanding of HDAC6's biological roles but also paves the way for developing HDAC6 inhibitors that could serve as effective therapeutic strategies against diseases characterized by dysregulated deacetylase activity. Given the rising interest in targeted therapies, further investigation into HDAC6's mechanisms and its role in disease etiology is essential for advancing therapeutic interventions.
